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Summa ry
The term, neurodegenerative disorders, implies that there is no exact knowledge of 
the cause or pathogenesis of these diseases. These diseases have been attracting great 
research interest, because drugs, able to influence their pathogenesis, are nőt available, 
and because their pathomechanism can be studied in animal models.
In the pathogenesis of Huntington’s disease (HD; an autosomal dominant 
hereditary neurodegenerative disorder) excitotoxicity likely plays an important role. 
Excitotoxicity includes a dysfunction of excitatory amino acid neurotransmission, usually 
a hyperstimulation of glutamate receptors. In the central nervous system, the striatum is 
the most glutamaceptive region and is thus predisposed to excitotoxicity. Excess 
activation of N-methyl-D-aspartate (NMDA) receptors induces apoptosis or necrosis of 
the cells expressing them, which will result in behavioural and functional disorders. Prior 
to cell death, dopaminergic neurons can be over-excited and can release dopamine (DA), 
which itself can be alsó neurotoxic.
Mitochondrial toxins -  such as 3-nitropropionic acid (3-NP) -  lead to a pattem of 
striatal atrophy similar to that seen in HD, and constitute so a tool in studying the disease 
in animal models. Beyond the histological effects themselves, bilateral striatal 
degeneration was shown to have neurobehavioural consequences. These included 
alteration of locomotor activity, startle reflex abnormalities, and reduced sensorimotor 
gating. In patients with HD, first hyper- then hypoactivity, and impaired pre-pulse 
inhibition (PPI), can be observed. Beside the pattem of striatal atrophy similar to that of 
HD, neurobehavioural alterations induced by 3-NP alsó underline its important role in 
modelling the disease.
In the background of 3-NP induced neurobehavioural alterations, both 
glutamatergic and dopaminergic functions are supposed. In order to investigate the action 
of 3-NP on these neurotransmitter systems, drugs which are known to act on these were 
chosen: the NMDA receptor antagonist, dizocilpine maleate (MK-801); the D2 receptor 
agonist, quinpirole (QP); and the D2 antagonist, sulpiride (SP).
The aim of the study was to reveal the mechanism of neurobehavioural alterations 
more in detail, thereby contributing to the improvement of the behavioural aspect of the
HD model, so that the potential protective agents could be investigated on behavioural, 
and nőt only histological, endpoints.
Aduit male Wistar rats were used in the behavioural experiments. Administration 
of the drugs and neurobehavioural investigations were done in two, “immediate” and 
“acute”, experimental schemes. The behavioural tests: open field (OF), rotarod, and 
acoustic startle response without (ASR) and with (PPI) pre-pulse stimulus were performed 
before drug application, and were repeated 30 after injection in the immediate, and 24 
after it in the acute scheme. 3-NP (20 mg/kg) and MK-801 (0.8 mg/kg) was given the rats 
by intraperitoneal injection, alone or combined. In the combination groups, 30 minutes 
were leit between injecting the flrst and the second drug. QP (5 mg/kg) or SP (80 mg/kg) 
was injected subcutaneously 15 min before the administration of 3-NP or MK-801. 
Controls were injected with saline.
The rats’ spontaneous exploratory activity was investigated in the OF apparátus 
(Conducta 1.0 System, Experimetria Ltd.) in 10-minute sessions. Ambulatory, vertical 
and local activity was computed on the basis of inffared beam interruptions detecting the 
animal’s movements.
Fór investigating the effects of drugs on motor coordination, the rats’ rotarod 
performance was tested. Before the beginning the experiment, the rats received a 
preliminary training on the rotarod (ROTA-ROD fór rats 47700, Ugo Basile, Italy) on 5 
consecutive days. In this test, we measured the time in seconds that the rats were able to 
spend on the rod, during the 300 sec session.
ASR was recorded fór assessing the drugs’ effects on sensorimotor reactivity. The 
rats were pút intő a sound-proof plexiglas chamber (Responder X System, Columbus 
Instrument, Ohio, USA) and, following a 10-15 min accommodation period, were 
exposed to a series of 10 startiing stimuli (5 kHz, 110 dB, 200 ms, 15 s interval). The 
vertical force associated with the startle response (whole-body muscle twitch) was 
measured by a piezoelectric force transducer. Following a 15 minutes recovery time, 
another session of 10 stimuli was started. This time a low-amplitude stimulus, a pre-pulse 
(1 kHz, 73 dB, 500 ms) was presented just before the startiing stimulus (inter-stimulus 
time: 200 ms). This “waming” pulse attenuates the level of the startle response, and this 
normál suppression of the ASR by a preceding stimulus is termed pre-pulse inhibition
(PPI). The number of noise-positive responses; and somé numeric parameters like latency, 
peak amplitude, and time to peak, of noise-positive responses were measured.
The number of noise-positive responses in the ASR and PPI test was evaluated by 
Chi2 test. Distribution of OF, rotarod and other ASR/PPI data was checked fór normality 
by Kolmogorov-Smimov test. In case of normál distribution, all behavioural data were 
tested by one-way analysis of variance (ANOVA) (post hoc Scheffe test, p<0.05. At non- 
normal distribution, by Kruskal-Wallis (post hoc Mann-Whitney test, p<0.05) was used. 
The software pack SPSS 9.0 was used to the statistical analysis. During the whole study, 
the principles of the Ethical Committee fór the Protection of Animals in Research of the 
University were strictly followed.
In the immediate experimental scheme, both 3-NP and MK-801 significantly 
decreased the totál open fíeld locomotor activity compared to the pre-administration self- 
control. Similar trend of motility was alsó observed in the combination groups. When 
given to the rats before 3-NP administration, both QP and SP caused further decrease of 
ambulatory activity compared to control. On the vertical activity, the effect of QP+3-NP 
and SP+3-NP was similar. QP+3-NP caused an increase in local motility, which was 
significant versus control and versus 3-NP group. QP and SP, combined with MK-801, 
significantly decreased the vertical activity versus control.
A single dose of MK-801 -  both alone and in combinations -  caused 
uncoordinated, ataxic gait in the rats, preventing any rotarod performance.
Significantly decreased number of ASR responses was seen in the MK-801 group 
compared to its own pre-administration control, and this diminishing trend was alsó seen 
following the combination treatments. The slight inhibition seen in the control group 
disappeared in the 3-NP treated group. When 3-NP was preceded by MK-801, somé 
inhibitory effect was again observed, bút in 3-NP+MK-801 group there was no inhibition 
at all. Latency of noise-positive acoustic startle responses was significantly decreased in 
the 3-NP treated rats. The changes induced by MK-801 alone were similar to those seen in 
the 3-NP group. In the MK-801+3-NP group, the effects were like and the decrease of 
time to peak was significant. In the test with pre-pulse stimulus, the peak amplitude was 
significantly lower in the 3-NP group versus the value obtained without pre-pulse.
When 3-NP was preceded by QP, significantly decreased, bút when by SP, 
significantly increased number of ASR noise-positive responses was observed. The slight
inhibitory effect, which was observed in the control group, disappeared in the 3-NP 
treated rats. However, combined with SP, a stronger pre-pulse inhibition was again 
observed. Combined with MK-801, signifícant contrary effects of QP and SP on MK-801 
altered noise-positive responses were nőt observed.
QP administration before 3-NP increased significantly the latency and time to peak 
of the ASR response compared to the 3-NP alone group, both without and with pre-pulse. 
ASR peak amplitude decreased significantly after QP+3-NP treatment versus 3-NP alone; 
bút in the SP+3-NP group, signifícant increase was seen in the same comparison. 
Opposite effects of QP and SP on the ASR response parameters were alsó seen on 
combination with MK-801 group, except peak amplitude in the test with pre-pulse.
Similar to their immediate effects, both 3-NP and MK-801 decreased the totál 
open field locomotor activity in alsó the acute experimental scheme, bút the decrease of 
ambulatory activity was less than it was 30 min after treatment. The 3-NP+MK-801 
combination had a similar effect, which was alsó signifícant. SP+3-NP treatment caused 
signifícant decrease of vertical activity versus control; and SP+MK-801, in the horizontal 
activity versus MK-801 alone.
The number of ASR responses showed increasing tendency in all groups. In the 3- 
NP and MK-801+3-NP treated rats, pronounced pre-pulse inhibition was seen.
In the 3-NP treated rats, latency of ASR decreased and peak amplitude increased 
significantly compared to the self-control groups. In the pre-pulse inhibition test, time to 
peak decreased significantly. These effects were alsó visible in the combined groups. The 
administration of QP or SP before 3-NP or MK-801 had minimál fiirther effect the 
number of nőise positive responses and on pre-pulse inhibition.
3-NP caused signifícant increase of peak amplitude, which was reduced 
significantly in the QP+3-NP group. In the pre-pulse inhibition test 3-NP decreased 
significantly the time to peak. When 3-NP was preceded by QP, peak amplitude decreased 
significantly.
The particular points of conclusion, déri ved írom the above results, are the following:
• 3-NP-induced reduced locomotor behaviour is consistent with decreased release and 
action of DA in the caudate-putamen, which confirms the present histological HD 
model.
• Reduction of DA release in the caudate-putamen is mediated by an indirect inhibitory 
mechanism of corticostriatal axons, which exert a dual presynaptic influence on 
dopamine release.
• The hypomotility induced by the NMDA-antagonist MK-801 was, in contrast to what 
could be expected on the basis of literature data, nőt opposite to that of 3-NP.
• Behavioral effects of 3-NP seem to rely, at least partly, on nőt only glutamatergic, 
bút on alsó other, that is, dopaminergic mechanisms.
• The positive effect of 3-NP on the startle response indicates increased DA release in 
the nucleus accumbens (NAC).
• When 3-NP was preceded by the postsynaptic D2 antagonist SP, diminished PPI 
induced by 3-NP became normál, which indicates the stimulant effect of 3-NP via 
postsynaptic D2 receptors in the NAC.
• 3-NP need nőt be applied so long as to destroy the striatal dopaminergic neurons fór 
a behavioural effect, which is relevant in modelling HD and indicates that the effect 
generated immediately is alsó based on dopaminergic deficit.
• Behavioural methods may give opportunity to monitor the effects of agents, inducing 
or preventing HD-relevant damage, in a non-invasive way, contrary to the present, 
histological models, where the tests are nőt repeatable.
• Beyond modelling HD, the present results may gain importance in improving the 
therapy of other chronic neurodegenerative diseases.
